Compare CASY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASY | RPRX |
|---|---|---|
| Founded | 1959 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5B | 19.7B |
| IPO Year | 1994 | 2020 |
| Metric | CASY | RPRX |
|---|---|---|
| Price | $658.17 | $45.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $667.18 | $47.75 |
| AVG Volume (30 Days) | 374.7K | ★ 2.8M |
| Earning Date | 03-09-2026 | 05-07-2026 |
| Dividend Yield | 0.34% | ★ 2.06% |
| EPS Growth | ★ 9.01 | N/A |
| EPS | ★ 14.79 | 1.78 |
| Revenue | ★ $15,940,899,000.00 | $2,378,193,000.00 |
| Revenue This Year | $10.63 | $38.30 |
| Revenue Next Year | $5.36 | $4.80 |
| P/E Ratio | $44.95 | ★ $25.55 |
| Revenue Growth | ★ 7.25 | 5.06 |
| 52 Week Low | $397.80 | $29.66 |
| 52 Week High | $694.93 | $47.86 |
| Indicator | CASY | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 50.40 |
| Support Level | $540.43 | $44.94 |
| Resistance Level | $684.33 | $46.14 |
| Average True Range (ATR) | 20.56 | 0.84 |
| MACD | -3.69 | -0.27 |
| Stochastic Oscillator | 45.27 | 18.37 |
Casey's General Stores Inc serves as convenience store chain with its 2,900 locations, positioned in the Midwest United States. About half of Casey's stores are located in rural towns with populations under 5,000. While fueling stations serve as a key traffic driver, about two-thirds of the company's gross profit stems from in-store sales of grocery items, prepared meals, and general merchandise. Casey's owns more than 90% of its stores and operates the majority of its warehousing and distribution processes internally.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.